Results 241 to 250 of about 284,082 (261)

Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe accumulation

Phytomedicine, 2023
Huajun Zhao, Zhiguo Zheng, Yifan Wang
exaly  

Targeted nanomedicine in cisplatin-based cancer therapeutics

Journal of Controlled Release, 2022
Junjie Li, Kazunori Kataoka, Panyue Wen
exaly  

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

Annals of Oncology, 2009
Yoon-Koo Kang, M Lichinitser, J Santamariá   +2 more
exaly  

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

Annals of Oncology, 2007
Y Ariyoshi, S Negoro, Y Nishiwaki
exaly  

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

Cancer Cell, 2018
Sumin Kang, Jun Fan, Lawrence H Boise
exaly  

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma

Annals of Oncology, 2012
William K. Oh, Matthew D Galsky, Joaquim Bellmunt   +2 more
exaly  

Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer

Annals of Oncology, 2015
C Hamada, H Imamura, N Sugimoto
exaly  

Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism

Cancer Letters, 2016
Zhen Fan, Zhihong Ai, Songbo Qiu
exaly  

Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer

Annals of Oncology, 2017
A Miki, N Hirabayashi, T Fukunaga
exaly